Adjusted revenue and EPS guidance for 2026 were raised, with strong organic growth in Consumables and Infusion Systems, while Vital Care declined due to the IV Solutions joint venture. Gross margin is projected at 41.5%, and capital expenditures are set at $85m–$100m.Original document: ICU Medical…
Adjusted revenue and EPS guidance for 2026 were raised, with strong organic growth in Consumables and Infusion Systems, while Vital Care declined due to the IV Solutions joint venture. Gross margin is projected at 41.5%, and capital expenditures are set at $85m–$100m.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
